Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Hologic, Inc.
75.7% sales growth and 46.05% return on equity
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, surgical products, and light-based aesthetic and medical treatment systems for women in the United States and internationally.
Hologic, Inc.'s sales growth this year is anticipated to be 35% and a negative 17.3% for next year.
Year-on-year quarterly revenue growth grew by 55.5%, now sitting on 3.78B for the twelve trailing months.
Hologic, Inc.'s sales growth is a negative 0% for the current quarter and 75.7% for the next. The company's growth estimates for the present quarter and the next is 252.5% and 243.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 46.05%.
Hologic, Inc.'s Stock Yearly Top and Bottom Value
Hologic, Inc.'s stock is valued at $74.32 at 10:22 EST, below its 52-week high of $77.49 and way above its 52-week low of $26.49.
Hologic, Inc.'s Moving Average
Hologic, Inc.'s worth is above its 50-day moving average of $70.90 and way above its 200-day moving average of $63.82.2. Horizon Therapeutics Public Limited Company
82.2% sales growth and 29.59% return on equity
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally.
Horizon Therapeutics Public Limited Company's sales growth this year is anticipated to be 64.1% and 38.3% for next year.
Year-on-year quarterly revenue growth grew by 89.7%, now sitting on 1.82B for the twelve trailing months.
Horizon Therapeutics Public Limited Company's sales growth for the next quarter is 82.2%. The company's growth estimates for the current quarter and the next is 82.1% and 150%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.59%.
Horizon Therapeutics Public Limited Company's Stock Yearly Top and Bottom Value
Horizon Therapeutics Public Limited Company's stock is valued at $75.57 at 10:22 EST, way below its 52-week high of $86.67 and way above its 52-week low of $23.81.
Horizon Therapeutics Public Limited Company's Moving Average
Horizon Therapeutics Public Limited Company's value is above its 50-day moving average of $72.87 and way higher than its 200-day moving average of $67.78.3. First Savings Financial Group, Inc.
25.5% sales growth and 24.45% return on equity
First Savings Financial Group, Inc. operates as the holding company for First Savings Bank that provides various banking products and services to consumers and businesses in southern Indiana.
First Savings Financial Group, Inc.'s sales growth this year is expected to be 12.3% and a negative 0% for next year.
Year-on-year quarterly revenue growth grew by 136.4%, now sitting on 172.55M for the twelve trailing months.
First Savings Financial Group, Inc.'s sales growth for the next quarter is 25.5%. The company's growth estimates for the present quarter and the next is 252.8% and 900%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.45%.
First Savings Financial Group, Inc.'s Stock Yearly Top and Bottom Value
First Savings Financial Group, Inc.'s stock is valued at $64.10 at 10:22 EST, under its 52-week high of $67.73 and way higher than its 52-week low of $29.50.
First Savings Financial Group, Inc.'s Moving Average
First Savings Financial Group, Inc.'s worth is above its 50-day moving average of $61.85 and way above its 200-day moving average of $49.89.4. Qualys, Inc.
12.4% sales growth and 23.23% return on equity
Qualys, Inc. provides cloud-based platform that delivers information technology (IT), security, and compliance solutions in the United States and internationally.
Qualys, Inc.'s sales growth this year is expected to be 12.8% and 12.5% for next year.
Year-on-year quarterly revenue growth grew by 12.6%, now sitting on 352.83M for the twelve trailing months.
Qualys, Inc.'s sales growth for the next quarter is 12.4%. The company's growth estimates for the ongoing quarter and the next is 9.4% and 6.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.23%.
Qualys, Inc.'s Stock Yearly Top and Bottom Value
Qualys, Inc.'s stock is valued at $95.05 at 10:22 EST, way under its 52-week high of $125.22 and way above its 52-week low of $63.37.
Qualys, Inc.'s Moving Average
Qualys, Inc.'s worth is higher than its 50-day moving average of $92.26 and below its 200-day moving average of $102.30.5. Baozun Inc.
43.5% sales growth and 8.13% return on equity
Baozun Inc. provides e-commerce solutions to brand partners in the People's Republic of China.
Baozun Inc.'s sales growth this year is anticipated to be 32.4% and 28.8% for next year.
Year-on-year quarterly revenue growth grew by 21.7%, now sitting on N/A for the twelve trailing months.
Baozun Inc.'s sales growth for the next quarter is 43.5%. The company's growth estimates for the present quarter and the next is 42.1% and 100%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.13%.
Baozun Inc.'s Stock Yearly Top and Bottom Value
Baozun Inc.'s stock is valued at $35.63 at 10:22 EST, way under its 52-week high of $47.51 and way above its 52-week low of $22.19.